GreenLight Biosciences Holdings

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, VRTX has a market cap of 113.6B. Regarding current trading prices, GRNAW is priced at $0.02, while VRTX trades at $442.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas VRTX's P/E ratio is 29.19. In terms of profitability, GRNAW's ROE is -18.47%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, GRNAW is less volatile compared to VRTX. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check VRTX's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, REGN has a market cap of 80.8B. Regarding current trading prices, GRNAW is priced at $0.02, while REGN trades at $753.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas REGN's P/E ratio is 18.73. In terms of profitability, GRNAW's ROE is -18.47%, compared to REGN's ROE of +0.15%. Regarding short-term risk, GRNAW is less volatile compared to REGN. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check REGN's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, GRNAW is priced at $0.02, while VRNA trades at $106.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas VRNA's P/E ratio is -102.80. In terms of profitability, GRNAW's ROE is -18.47%, compared to VRNA's ROE of -0.30%. Regarding short-term risk, GRNAW and VRNA have similar daily volatility (0.00).Check VRNA's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, ARGX has a market cap of 46B. Regarding current trading prices, GRNAW is priced at $0.02, while ARGX trades at $747.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas ARGX's P/E ratio is 37.93. In terms of profitability, GRNAW's ROE is -18.47%, compared to ARGX's ROE of +0.34%. Regarding short-term risk, GRNAW is less volatile compared to ARGX. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check ARGX's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, ALNY has a market cap of 43.6B. Regarding current trading prices, GRNAW is priced at $0.02, while ALNY trades at $320.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas ALNY's P/E ratio is 141.74. In terms of profitability, GRNAW's ROE is -18.47%, compared to ALNY's ROE of +0.90%. Regarding short-term risk, GRNAW is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check ALNY's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, GRNAW is priced at $0.02, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas SGEN's P/E ratio is -57.19. In terms of profitability, GRNAW's ROE is -18.47%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, GRNAW is less volatile compared to SGEN. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check SGEN's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, INSM has a market cap of 35.5B. Regarding current trading prices, GRNAW is priced at $0.02, while INSM trades at $158.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas INSM's P/E ratio is -27.34. In terms of profitability, GRNAW's ROE is -18.47%, compared to INSM's ROE of -1.68%. Regarding short-term risk, GRNAW is less volatile compared to INSM. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check INSM's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, UTHR has a market cap of 25B. Regarding current trading prices, GRNAW is priced at $0.02, while UTHR trades at $557.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas UTHR's P/E ratio is 20.47. In terms of profitability, GRNAW's ROE is -18.47%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, GRNAW is less volatile compared to UTHR. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check UTHR's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, BNTX has a market cap of 22.5B. Regarding current trading prices, GRNAW is priced at $0.02, while BNTX trades at $89.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas BNTX's P/E ratio is -16.50. In terms of profitability, GRNAW's ROE is -18.47%, compared to BNTX's ROE of -0.06%. Regarding short-term risk, GRNAW is less volatile compared to BNTX. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check BNTX's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, RPRX has a market cap of 20.8B. Regarding current trading prices, GRNAW is priced at $0.02, while RPRX trades at $48.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas RPRX's P/E ratio is 27.24. In terms of profitability, GRNAW's ROE is -18.47%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, GRNAW is less volatile compared to RPRX. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check RPRX's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, GRNAW is priced at $0.02, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas BGNE's P/E ratio is -22.55. In terms of profitability, GRNAW's ROE is -18.47%, compared to BGNE's ROE of +0.07%. Regarding short-term risk, GRNAW is less volatile compared to BGNE. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check BGNE's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, ROIV has a market cap of 19.9B. Regarding current trading prices, GRNAW is priced at $0.02, while ROIV trades at $28.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas ROIV's P/E ratio is -23.79. In terms of profitability, GRNAW's ROE is -18.47%, compared to ROIV's ROE of -0.18%. Regarding short-term risk, GRNAW is less volatile compared to ROIV. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check ROIV's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, MRNA has a market cap of 19.8B. Regarding current trading prices, GRNAW is priced at $0.02, while MRNA trades at $49.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas MRNA's P/E ratio is -6.89. In terms of profitability, GRNAW's ROE is -18.47%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, GRNAW is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check MRNA's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, RVMD has a market cap of 19.5B. Regarding current trading prices, GRNAW is priced at $0.02, while RVMD trades at $99.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas RVMD's P/E ratio is -16.58. In terms of profitability, GRNAW's ROE is -18.47%, compared to RVMD's ROE of -0.63%. Regarding short-term risk, GRNAW is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check RVMD's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, INCY has a market cap of 18.8B. Regarding current trading prices, GRNAW is priced at $0.02, while INCY trades at $94.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas INCY's P/E ratio is 14.71. In terms of profitability, GRNAW's ROE is -18.47%, compared to INCY's ROE of +0.29%. Regarding short-term risk, GRNAW is less volatile compared to INCY. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check INCY's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, GRNAW is priced at $0.02, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, GRNAW's ROE is -18.47%, compared to DNA-WT's ROE of -0.54%. Regarding short-term risk, GRNAW is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check DNA-WT's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, GMAB has a market cap of 16.8B. Regarding current trading prices, GRNAW is priced at $0.02, while GMAB trades at $27.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas GMAB's P/E ratio is 17.68. In terms of profitability, GRNAW's ROE is -18.47%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, GRNAW is less volatile compared to GMAB. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check GMAB's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, BBIO has a market cap of 14.4B. Regarding current trading prices, GRNAW is priced at $0.02, while BBIO trades at $73.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas BBIO's P/E ratio is -19.70. In terms of profitability, GRNAW's ROE is -18.47%, compared to BBIO's ROE of +0.39%. Regarding short-term risk, GRNAW is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check BBIO's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, SMMT has a market cap of 14.1B. Regarding current trading prices, GRNAW is priced at $0.02, while SMMT trades at $19.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas SMMT's P/E ratio is -13.14. In terms of profitability, GRNAW's ROE is -18.47%, compared to SMMT's ROE of -2.97%. Regarding short-term risk, GRNAW is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check SMMT's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, ASND has a market cap of 14B. Regarding current trading prices, GRNAW is priced at $0.02, while ASND trades at $225.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas ASND's P/E ratio is -52.59. In terms of profitability, GRNAW's ROE is -18.47%, compared to ASND's ROE of +1.28%. Regarding short-term risk, GRNAW is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check ASND's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, GRNAW is priced at $0.02, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas KRTX's P/E ratio is -28.09. In terms of profitability, GRNAW's ROE is -18.47%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, GRNAW is less volatile compared to KRTX. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check KRTX's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, IONS has a market cap of 12.4B. Regarding current trading prices, GRNAW is priced at $0.02, while IONS trades at $74.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas IONS's P/E ratio is -31.57. In terms of profitability, GRNAW's ROE is -18.47%, compared to IONS's ROE of -0.69%. Regarding short-term risk, GRNAW is less volatile compared to IONS. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check IONS's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, MDGL has a market cap of 12.2B. Regarding current trading prices, GRNAW is priced at $0.02, while MDGL trades at $530.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas MDGL's P/E ratio is -41.26. In terms of profitability, GRNAW's ROE is -18.47%, compared to MDGL's ROE of -0.44%. Regarding short-term risk, GRNAW is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check MDGL's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, EXEL has a market cap of 11.8B. Regarding current trading prices, GRNAW is priced at $0.02, while EXEL trades at $43.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas EXEL's P/E ratio is 15.84. In terms of profitability, GRNAW's ROE is -18.47%, compared to EXEL's ROE of +0.37%. Regarding short-term risk, GRNAW is less volatile compared to EXEL. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check EXEL's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, JAZZ has a market cap of 11.6B. Regarding current trading prices, GRNAW is priced at $0.02, while JAZZ trades at $187.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas JAZZ's P/E ratio is -32.24. In terms of profitability, GRNAW's ROE is -18.47%, compared to JAZZ's ROE of -0.09%. Regarding short-term risk, GRNAW is less volatile compared to JAZZ. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check JAZZ's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, GRNAW is priced at $0.02, while RNAM trades at $72.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas RNAM's P/E ratio is -17.39. In terms of profitability, GRNAW's ROE is -18.47%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, GRNAW and RNAM have similar daily volatility (0.00).Check RNAM's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, BMRN has a market cap of 11B. Regarding current trading prices, GRNAW is priced at $0.02, while BMRN trades at $55.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas BMRN's P/E ratio is 31.80. In terms of profitability, GRNAW's ROE is -18.47%, compared to BMRN's ROE of +0.06%. Regarding short-term risk, GRNAW is less volatile compared to BMRN. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check BMRN's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, GRNAW is priced at $0.02, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas RXDX's P/E ratio is -56.47. In terms of profitability, GRNAW's ROE is -18.47%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, GRNAW is less volatile compared to RXDX. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check RXDX's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, ARWR has a market cap of 8.8B. Regarding current trading prices, GRNAW is priced at $0.02, while ARWR trades at $62.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas ARWR's P/E ratio is 39.32. In terms of profitability, GRNAW's ROE is -18.47%, compared to ARWR's ROE of +0.36%. Regarding short-term risk, GRNAW is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check ARWR's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, AXSM has a market cap of 8.8B. Regarding current trading prices, GRNAW is priced at $0.02, while AXSM trades at $168.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas AXSM's P/E ratio is -46.68. In terms of profitability, GRNAW's ROE is -18.47%, compared to AXSM's ROE of -2.54%. Regarding short-term risk, GRNAW is less volatile compared to AXSM. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check AXSM's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, GRNAW is priced at $0.02, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas IMGN's P/E ratio is -111.55. In terms of profitability, GRNAW's ROE is -18.47%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, GRNAW is less volatile compared to IMGN. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check IMGN's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, PCVX has a market cap of 8.4B. Regarding current trading prices, GRNAW is priced at $0.02, while PCVX trades at $57.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas PCVX's P/E ratio is -10.39. In terms of profitability, GRNAW's ROE is -18.47%, compared to PCVX's ROE of -0.26%. Regarding short-term risk, GRNAW is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check PCVX's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, TECH has a market cap of 8.4B. Regarding current trading prices, GRNAW is priced at $0.02, while TECH trades at $53.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas TECH's P/E ratio is 100.91. In terms of profitability, GRNAW's ROE is -18.47%, compared to TECH's ROE of +0.04%. Regarding short-term risk, GRNAW is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check TECH's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, GRNAW is priced at $0.02, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas BPMC's P/E ratio is -51.58. In terms of profitability, GRNAW's ROE is -18.47%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, GRNAW and BPMC have similar daily volatility (0.00).Check BPMC's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, CYTK has a market cap of 8.2B. Regarding current trading prices, GRNAW is priced at $0.02, while CYTK trades at $66.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas CYTK's P/E ratio is -10.19. In terms of profitability, GRNAW's ROE is -18.47%, compared to CYTK's ROE of +1.73%. Regarding short-term risk, GRNAW is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check CYTK's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, GRNAW is priced at $0.02, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas CERE's P/E ratio is -16.47. In terms of profitability, GRNAW's ROE is -18.47%, compared to CERE's ROE of -0.72%. Regarding short-term risk, GRNAW is less volatile compared to CERE. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check CERE's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, NUVL has a market cap of 7.7B. Regarding current trading prices, GRNAW is priced at $0.02, while NUVL trades at $104.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas NUVL's P/E ratio is -18.06. In terms of profitability, GRNAW's ROE is -18.47%, compared to NUVL's ROE of -0.42%. Regarding short-term risk, GRNAW is less volatile compared to NUVL. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check NUVL's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, HALO has a market cap of 7.7B. Regarding current trading prices, GRNAW is priced at $0.02, while HALO trades at $64.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas HALO's P/E ratio is 25.55. In terms of profitability, GRNAW's ROE is -18.47%, compared to HALO's ROE of +0.93%. Regarding short-term risk, GRNAW is less volatile compared to HALO. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check HALO's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, KRYS has a market cap of 7.6B. Regarding current trading prices, GRNAW is priced at $0.02, while KRYS trades at $257.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas KRYS's P/E ratio is 37.80. In terms of profitability, GRNAW's ROE is -18.47%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, GRNAW is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check KRYS's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, ABVX has a market cap of 7.5B. Regarding current trading prices, GRNAW is priced at $0.02, while ABVX trades at $118.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas ABVX's P/E ratio is -20.60. In terms of profitability, GRNAW's ROE is -18.47%, compared to ABVX's ROE of -1.59%. Regarding short-term risk, GRNAW is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check ABVX's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, GRNAW is priced at $0.02, while MTSR trades at $70.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas MTSR's P/E ratio is -23.58. In terms of profitability, GRNAW's ROE is -18.47%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, GRNAW is less volatile compared to MTSR. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check MTSR's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, IBRX has a market cap of 7.3B. Regarding current trading prices, GRNAW is priced at $0.02, while IBRX trades at $7.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas IBRX's P/E ratio is -18.79. In terms of profitability, GRNAW's ROE is -18.47%, compared to IBRX's ROE of +0.64%. Regarding short-term risk, GRNAW is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check IBRX's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, KYMR has a market cap of 6.9B. Regarding current trading prices, GRNAW is priced at $0.02, while KYMR trades at $85.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas KYMR's P/E ratio is -23.02. In terms of profitability, GRNAW's ROE is -18.47%, compared to KYMR's ROE of -0.29%. Regarding short-term risk, GRNAW is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check KYMR's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, GRNAW is priced at $0.02, while MRUS trades at $90.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas MRUS's P/E ratio is -17.05. In terms of profitability, GRNAW's ROE is -18.47%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, GRNAW and MRUS have similar daily volatility (0.00).Check MRUS's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, PRAX has a market cap of 6.8B. Regarding current trading prices, GRNAW is priced at $0.02, while PRAX trades at $314.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas PRAX's P/E ratio is -23.67. In terms of profitability, GRNAW's ROE is -18.47%, compared to PRAX's ROE of -0.59%. Regarding short-term risk, GRNAW is less volatile compared to PRAX. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check PRAX's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, GRNAW is priced at $0.02, while ACLX trades at $114.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas ACLX's P/E ratio is -28.19. In terms of profitability, GRNAW's ROE is -18.47%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, GRNAW is less volatile compared to ACLX. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check ACLX's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, PTGX has a market cap of 6.6B. Regarding current trading prices, GRNAW is priced at $0.02, while PTGX trades at $103.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas PTGX's P/E ratio is -50.57. In terms of profitability, GRNAW's ROE is -18.47%, compared to PTGX's ROE of -0.20%. Regarding short-term risk, GRNAW is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check PTGX's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, BLTE has a market cap of 6.6B. Regarding current trading prices, GRNAW is priced at $0.02, while BLTE trades at $171.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas BLTE's P/E ratio is -72.40. In terms of profitability, GRNAW's ROE is -18.47%, compared to BLTE's ROE of -0.43%. Regarding short-term risk, GRNAW is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check BLTE's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, GRNAW is priced at $0.02, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas RETA's P/E ratio is -66.29. In terms of profitability, GRNAW's ROE is -18.47%, compared to RETA's ROE of +0.47%. Regarding short-term risk, GRNAW is less volatile compared to RETA. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check RETA's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, RYTM has a market cap of 6B. Regarding current trading prices, GRNAW is priced at $0.02, while RYTM trades at $87.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas RYTM's P/E ratio is -28.33. In terms of profitability, GRNAW's ROE is -18.47%, compared to RYTM's ROE of -1.79%. Regarding short-term risk, GRNAW is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check RYTM's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, ALKS has a market cap of 5.8B. Regarding current trading prices, GRNAW is priced at $0.02, while ALKS trades at $34.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas ALKS's P/E ratio is 24.51. In terms of profitability, GRNAW's ROE is -18.47%, compared to ALKS's ROE of +0.14%. Regarding short-term risk, GRNAW is less volatile compared to ALKS. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check ALKS's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, COGT has a market cap of 5.7B. Regarding current trading prices, GRNAW is priced at $0.02, while COGT trades at $34.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas COGT's P/E ratio is -16.31. In terms of profitability, GRNAW's ROE is -18.47%, compared to COGT's ROE of -1.00%. Regarding short-term risk, GRNAW is less volatile compared to COGT. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check COGT's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, PTCT has a market cap of 5.7B. Regarding current trading prices, GRNAW is priced at $0.02, while PTCT trades at $67.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas PTCT's P/E ratio is 8.01. In terms of profitability, GRNAW's ROE is -18.47%, compared to PTCT's ROE of -3.62%. Regarding short-term risk, GRNAW is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check PTCT's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, SRRK has a market cap of 5.7B. Regarding current trading prices, GRNAW is priced at $0.02, while SRRK trades at $49.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas SRRK's P/E ratio is -15.00. In terms of profitability, GRNAW's ROE is -18.47%, compared to SRRK's ROE of -1.46%. Regarding short-term risk, GRNAW is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check SRRK's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, CGON has a market cap of 5.6B. Regarding current trading prices, GRNAW is priced at $0.02, while CGON trades at $67.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas CGON's P/E ratio is -32.11. In terms of profitability, GRNAW's ROE is -18.47%, compared to CGON's ROE of -0.23%. Regarding short-term risk, GRNAW is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check CGON's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, GRNAW is priced at $0.02, while CDTX trades at $221.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas CDTX's P/E ratio is -19.77. In terms of profitability, GRNAW's ROE is -18.47%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, GRNAW and CDTX have similar daily volatility (0.00).Check CDTX's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, GRNAW is priced at $0.02, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, GRNAW's ROE is -18.47%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, GRNAW is less volatile compared to ABCM. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check ABCM's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, GRNAW is priced at $0.02, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas ISEE's P/E ratio is -22.44. In terms of profitability, GRNAW's ROE is -18.47%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, GRNAW is less volatile compared to ISEE. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check ISEE's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, CELC has a market cap of 5.5B. Regarding current trading prices, GRNAW is priced at $0.02, while CELC trades at $112.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas CELC's P/E ratio is -29.80. In terms of profitability, GRNAW's ROE is -18.47%, compared to CELC's ROE of -2.03%. Regarding short-term risk, GRNAW is less volatile compared to CELC. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check CELC's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, CAI has a market cap of 5.4B. Regarding current trading prices, GRNAW is priced at $0.02, while CAI trades at $19.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas CAI's P/E ratio is -5.94. In terms of profitability, GRNAW's ROE is -18.47%, compared to CAI's ROE of +0.25%. Regarding short-term risk, GRNAW is less volatile compared to CAI. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check CAI's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, TGTX has a market cap of 5.4B. Regarding current trading prices, GRNAW is priced at $0.02, while TGTX trades at $33.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas TGTX's P/E ratio is 12.12. In terms of profitability, GRNAW's ROE is -18.47%, compared to TGTX's ROE of +1.01%. Regarding short-term risk, GRNAW is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check TGTX's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, CNTA has a market cap of 5.4B. Regarding current trading prices, GRNAW is priced at $0.02, while CNTA trades at $39.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas CNTA's P/E ratio is -21.09. In terms of profitability, GRNAW's ROE is -18.47%, compared to CNTA's ROE of -0.51%. Regarding short-term risk, GRNAW is less volatile compared to CNTA. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check CNTA's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, FBIOX has a market cap of 5.4B. Regarding current trading prices, GRNAW is priced at $0.02, while FBIOX trades at $25.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas FBIOX's P/E ratio is N/A. In terms of profitability, GRNAW's ROE is -18.47%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, GRNAW and FBIOX have similar daily volatility (0.00).Check FBIOX's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, APLS has a market cap of 5.2B. Regarding current trading prices, GRNAW is priced at $0.02, while APLS trades at $40.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas APLS's P/E ratio is 224.39. In terms of profitability, GRNAW's ROE is -18.47%, compared to APLS's ROE of +0.08%. Regarding short-term risk, GRNAW is less volatile compared to APLS. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check APLS's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, ERAS has a market cap of 5.2B. Regarding current trading prices, GRNAW is priced at $0.02, while ERAS trades at $17.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas ERAS's P/E ratio is -37.73. In terms of profitability, GRNAW's ROE is -18.47%, compared to ERAS's ROE of -0.34%. Regarding short-term risk, GRNAW is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check ERAS's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, IMVT has a market cap of 5.1B. Regarding current trading prices, GRNAW is priced at $0.02, while IMVT trades at $24.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas IMVT's P/E ratio is -9.40. In terms of profitability, GRNAW's ROE is -18.47%, compared to IMVT's ROE of -0.66%. Regarding short-term risk, GRNAW is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check IMVT's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, GRNAW is priced at $0.02, while TERN trades at $52.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas TERN's P/E ratio is -51.25. In terms of profitability, GRNAW's ROE is -18.47%, compared to TERN's ROE of -0.20%. Regarding short-term risk, GRNAW is less volatile compared to TERN. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check TERN's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, MIRM has a market cap of 4.7B. Regarding current trading prices, GRNAW is priced at $0.02, while MIRM trades at $93.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas MIRM's P/E ratio is -201.32. In terms of profitability, GRNAW's ROE is -18.47%, compared to MIRM's ROE of -0.09%. Regarding short-term risk, GRNAW is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check MIRM's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, APGE has a market cap of 4.7B. Regarding current trading prices, GRNAW is priced at $0.02, while APGE trades at $83.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas APGE's P/E ratio is -19.96. In terms of profitability, GRNAW's ROE is -18.47%, compared to APGE's ROE of -0.37%. Regarding short-term risk, GRNAW is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check APGE's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, CRSP has a market cap of 4.7B. Regarding current trading prices, GRNAW is priced at $0.02, while CRSP trades at $48.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas CRSP's P/E ratio is -7.54. In terms of profitability, GRNAW's ROE is -18.47%, compared to CRSP's ROE of -0.32%. Regarding short-term risk, GRNAW is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check CRSP's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, GRNAW is priced at $0.02, while FOLD trades at $14.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas FOLD's P/E ratio is -160.44. In terms of profitability, GRNAW's ROE is -18.47%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, GRNAW is less volatile compared to FOLD. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check FOLD's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, GRNAW is priced at $0.02, while AKRO trades at $54.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas AKRO's P/E ratio is -14.57. In terms of profitability, GRNAW's ROE is -18.47%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, GRNAW is less volatile compared to AKRO. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check AKRO's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, XENE has a market cap of 4.5B. Regarding current trading prices, GRNAW is priced at $0.02, while XENE trades at $56.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas XENE's P/E ratio is -13.00. In terms of profitability, GRNAW's ROE is -18.47%, compared to XENE's ROE of -0.56%. Regarding short-term risk, GRNAW is less volatile compared to XENE. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check XENE's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, CORT has a market cap of 4.5B. Regarding current trading prices, GRNAW is priced at $0.02, while CORT trades at $42.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas CORT's P/E ratio is 51.20. In terms of profitability, GRNAW's ROE is -18.47%, compared to CORT's ROE of +0.15%. Regarding short-term risk, GRNAW is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check CORT's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, GRNAW is priced at $0.02, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas ALPN's P/E ratio is -101.52. In terms of profitability, GRNAW's ROE is -18.47%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, GRNAW is less volatile compared to ALPN. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check ALPN's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, GRNAW is priced at $0.02, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas OPT's P/E ratio is -1.52. In terms of profitability, GRNAW's ROE is -18.47%, compared to OPT's ROE of +0.88%. Regarding short-term risk, GRNAW and OPT have similar daily volatility (0.00).Check OPT's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, GRNAW is priced at $0.02, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas MRTX's P/E ratio is -4.82. In terms of profitability, GRNAW's ROE is -18.47%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, GRNAW is less volatile compared to MRTX. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check MRTX's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, LGND has a market cap of 4B. Regarding current trading prices, GRNAW is priced at $0.02, while LGND trades at $199.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas LGND's P/E ratio is 32.62. In terms of profitability, GRNAW's ROE is -18.47%, compared to LGND's ROE of +0.14%. Regarding short-term risk, GRNAW is less volatile compared to LGND. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check LGND's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, CRNX has a market cap of 3.8B. Regarding current trading prices, GRNAW is priced at $0.02, while CRNX trades at $36.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas CRNX's P/E ratio is -7.39. In terms of profitability, GRNAW's ROE is -18.47%, compared to CRNX's ROE of -0.41%. Regarding short-term risk, GRNAW is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check CRNX's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, VKTX has a market cap of 3.8B. Regarding current trading prices, GRNAW is priced at $0.02, while VKTX trades at $34.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas VKTX's P/E ratio is -10.33. In terms of profitability, GRNAW's ROE is -18.47%, compared to VKTX's ROE of -0.48%. Regarding short-term risk, GRNAW is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check VKTX's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, ACAD has a market cap of 3.8B. Regarding current trading prices, GRNAW is priced at $0.02, while ACAD trades at $22.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas ACAD's P/E ratio is 9.70. In terms of profitability, GRNAW's ROE is -18.47%, compared to ACAD's ROE of +0.42%. Regarding short-term risk, GRNAW is less volatile compared to ACAD. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check ACAD's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, NAMS has a market cap of 3.8B. Regarding current trading prices, GRNAW is priced at $0.02, while NAMS trades at $32.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas NAMS's P/E ratio is -19.08. In terms of profitability, GRNAW's ROE is -18.47%, compared to NAMS's ROE of -0.27%. Regarding short-term risk, GRNAW is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check NAMS's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, GRNAW is priced at $0.02, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas RYZB's P/E ratio is -57.86. In terms of profitability, GRNAW's ROE is -18.47%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, GRNAW is less volatile compared to RYZB. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check RYZB's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, GRNAW is priced at $0.02, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas CBAY's P/E ratio is -32.81. In terms of profitability, GRNAW's ROE is -18.47%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, GRNAW is less volatile compared to CBAY. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check CBAY's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, KNSA has a market cap of 3.6B. Regarding current trading prices, GRNAW is priced at $0.02, while KNSA trades at $48.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas KNSA's P/E ratio is 64.17. In terms of profitability, GRNAW's ROE is -18.47%, compared to KNSA's ROE of +0.11%. Regarding short-term risk, GRNAW is less volatile compared to KNSA. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check KNSA's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, EWTX has a market cap of 3.6B. Regarding current trading prices, GRNAW is priced at $0.02, while EWTX trades at $33.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas EWTX's P/E ratio is -20.33. In terms of profitability, GRNAW's ROE is -18.47%, compared to EWTX's ROE of -0.32%. Regarding short-term risk, GRNAW is less volatile compared to EWTX. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check EWTX's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, GRNAW is priced at $0.02, while SWTX trades at $46.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas SWTX's P/E ratio is -13.78. In terms of profitability, GRNAW's ROE is -18.47%, compared to SWTX's ROE of -0.45%. Regarding short-term risk, GRNAW and SWTX have similar daily volatility (0.00).Check SWTX's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, LEGN has a market cap of 3.5B. Regarding current trading prices, GRNAW is priced at $0.02, while LEGN trades at $19.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas LEGN's P/E ratio is -11.76. In terms of profitability, GRNAW's ROE is -18.47%, compared to LEGN's ROE of -0.29%. Regarding short-term risk, GRNAW is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check LEGN's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, LQDA has a market cap of 3.3B. Regarding current trading prices, GRNAW is priced at $0.02, while LQDA trades at $37.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas LQDA's P/E ratio is -46.84. In terms of profitability, GRNAW's ROE is -18.47%, compared to LQDA's ROE of -2.09%. Regarding short-term risk, GRNAW is less volatile compared to LQDA. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check LQDA's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, DNTH has a market cap of 3.2B. Regarding current trading prices, GRNAW is priced at $0.02, while DNTH trades at $86.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas DNTH's P/E ratio is -20.13. In terms of profitability, GRNAW's ROE is -18.47%, compared to DNTH's ROE of +0.00%. Regarding short-term risk, GRNAW is less volatile compared to DNTH. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check DNTH's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, TLX has a market cap of 3.1B. Regarding current trading prices, GRNAW is priced at $0.02, while TLX trades at $9.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas TLX's P/E ratio is -462.00. In terms of profitability, GRNAW's ROE is -18.47%, compared to TLX's ROE of -0.02%. Regarding short-term risk, GRNAW is less volatile compared to TLX. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check TLX's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, DNLI has a market cap of 3.1B. Regarding current trading prices, GRNAW is priced at $0.02, while DNLI trades at $20.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas DNLI's P/E ratio is -6.63. In terms of profitability, GRNAW's ROE is -18.47%, compared to DNLI's ROE of -0.50%. Regarding short-term risk, GRNAW is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check DNLI's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, CPRX has a market cap of 3.1B. Regarding current trading prices, GRNAW is priced at $0.02, while CPRX trades at $24.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas CPRX's P/E ratio is 14.77. In terms of profitability, GRNAW's ROE is -18.47%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, GRNAW is less volatile compared to CPRX. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check CPRX's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, ARQT has a market cap of 3B. Regarding current trading prices, GRNAW is priced at $0.02, while ARQT trades at $23.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas ARQT's P/E ratio is -185.38. In terms of profitability, GRNAW's ROE is -18.47%, compared to ARQT's ROE of -0.10%. Regarding short-term risk, GRNAW is less volatile compared to ARQT. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check ARQT's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, TARS has a market cap of 3B. Regarding current trading prices, GRNAW is priced at $0.02, while TARS trades at $70.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas TARS's P/E ratio is -44.16. In terms of profitability, GRNAW's ROE is -18.47%, compared to TARS's ROE of -0.20%. Regarding short-term risk, GRNAW is less volatile compared to TARS. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check TARS's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, DYN has a market cap of 3B. Regarding current trading prices, GRNAW is priced at $0.02, while DYN trades at $18.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas DYN's P/E ratio is -5.22. In terms of profitability, GRNAW's ROE is -18.47%, compared to DYN's ROE of -0.61%. Regarding short-term risk, GRNAW is less volatile compared to DYN. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check DYN's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, SYRE has a market cap of 3B. Regarding current trading prices, GRNAW is priced at $0.02, while SYRE trades at $47.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas SYRE's P/E ratio is -24.70. In terms of profitability, GRNAW's ROE is -18.47%, compared to SYRE's ROE of -0.29%. Regarding short-term risk, GRNAW is less volatile compared to SYRE. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check SYRE's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, TVTX has a market cap of 2.9B. Regarding current trading prices, GRNAW is priced at $0.02, while TVTX trades at $30.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas TVTX's P/E ratio is -59.29. In terms of profitability, GRNAW's ROE is -18.47%, compared to TVTX's ROE of -0.79%. Regarding short-term risk, GRNAW is less volatile compared to TVTX. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check TVTX's competition here

GRNAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRNAW stands at 0. In comparison, VERA has a market cap of 2.9B. Regarding current trading prices, GRNAW is priced at $0.02, while VERA trades at $40.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRNAW currently has a P/E ratio of N/A, whereas VERA's P/E ratio is -8.69. In terms of profitability, GRNAW's ROE is -18.47%, compared to VERA's ROE of -0.60%. Regarding short-term risk, GRNAW is less volatile compared to VERA. This indicates potentially lower risk in terms of short-term price fluctuations for GRNAW.Check VERA's competition here